Gross profits of Swedish biopharmaceutical company Sobi increased every year since 2011. The increase was especially significant during the latest years of the observed period. In 2024, the gross profit of Sobi stood at more than 20 billion Swedish kronor. The company's full name is Swedish Orphan Biovitrum AB. Sobi is specialized on the treatment of rare diseases.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Sobi, & Nasdaq Nordic. (March 31, 2025). Gross profit of Sobi from 2009 to 2024 (in million SEK) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 26, 2026, from /statistics/946970/gross-profit-of-sobi/
Sobi, und Nasdaq Nordic. "Gross profit of Sobi from 2009 to 2024 (in million SEK)." Chart. March 31, 2025. ÌÇÐÄÆƽâ°æ. Accessed July 26, 2026. /statistics/946970/gross-profit-of-sobi/
Sobi, Nasdaq Nordic. (2025). Gross profit of Sobi from 2009 to 2024 (in million SEK). ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 26, 2026. /statistics/946970/gross-profit-of-sobi/
Sobi, and Nasdaq Nordic. "Gross Profit of Sobi from 2009 to 2024 (in Million Sek)." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 31 Mar 2025, /statistics/946970/gross-profit-of-sobi/
Sobi & Nasdaq Nordic, Gross profit of Sobi from 2009 to 2024 (in million SEK) ÌÇÐÄÆƽâ°æ, /statistics/946970/gross-profit-of-sobi/ (last visited July 26, 2026)
Gross profit of Sobi from 2009 to 2024 (in million SEK) [Graph], Sobi, & Nasdaq Nordic, March 31, 2025. [Online]. Available: /statistics/946970/gross-profit-of-sobi/
